RxDoctor Payments Data

Alexa Murray, APRN

Family · Sandusky, OHNPI 1922587948

Payments from drug & device makers

$2,527in general payments, 2019–2025

Across 142 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$649
  • AstraZeneca$539
  • Biohaven Pharmaceutical Holding Company Ltd.$253
  • Pfizer$192
  • GSK$129
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$102
  • plus $663 from 17 others

What the payments were for

  • Food & beverage$2,527100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,527 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$233
Medicare patients
15
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$43,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$40,859
JanuviaSitagliptin Phosphate29$27,666
JardianceEmpagliflozin26$26,019
TrulicityDulaglutide12$17,201
EliquisApixaban18$15,025
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,919
Albuterol Sulfate HfaAlbuterol Sulfate147$3,416
SymbicortBudesonide/Formoterol Fumarate11$2,292
Duloxetine Hcl65$2,148
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$1,842
Ondansetron Hcl26$1,681
Gabapentin167$1,634
Omeprazole160$1,525
Pregabalin55$1,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$43,44639 claims
GSKTrelegy Ellipta$129$40,85946 claims
MerckJanuvia$36$27,66629 claims
Boehringer IngelheimJardiance$68$26,01926 claims
Lilly USA, LLCTrulicity$31$17,20112 claims
AstraZenecaBreztri Aerosphere, Symbicort$539$15,21129 claims
PfizerEliquis$192$15,02518 claims
AbbVieSynthroid$649$62612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →